Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JUPITER Not Enough To Expand CRP Testing Indication, Experts Say

This article was originally published in The Gray Sheet

Executive Summary

Experts are not ready to call for an expansion of high-sensitivity C-reactive protein (hsCRP) testing, even though new trial results show elevated CRP testing can identify patients with low cholesterol who might benefit from statin drugs
Advertisement

Related Content

Nontraditional Risk Factors For Heart Disease Require More Study
Nontraditional Risk Factors For Heart Disease Require More Study
JUPITER Shines Celestial Glow On Statin Use; Docs Ready, But Are Payers?
Advertisement
UsernamePublicRestriction

Register

MT026803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel